HBV
Conditions
Interventions
Group 1:Levamisole coating agent + PEG-IFN- a- 2B + nucleoside analogues
Group 2:Levamisole coating agent + PEG-IFN- a- 2B
Group 3:Levamisole coating agent +nucleoside analogues
Group 4: PEG-IFN-a-2b
Group 5:nucleoside analogues
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient must sign the informed consent and voluntarily accept the follow-up for at least 24 weeks; 2. Aged 18 to 75 years, gender is not limited; 3. Comply with the indications for antiviral treatment of the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition)"; 4. All patients signed the "Informed Consent" with full knowledge, understanding and voluntariness.
Exclusion criteria
Exclusion criteria: 1. Child-Pugh rating C; 2. Neutrophil count <0.5x10^9/L, or platelets <25x10^9/L; 3. A clear diagnosis of patients with anxiety or depression; 4. Pregnant women and lactating women; 5. Diabetic patients with poor blood sugar control; 6. Patients with poorly controlled hypertension and blood pressure; 7. The investigator believes that there are any other factors that are not suitable for inclusion or that affect subjects participating in or completing the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA;the quantitation of HBV markers; | — |
Countries
China
Contacts
Public ContactLu Xiaobo
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed